Sangamo Therapeutics Inc (SGMO) Receives $18.80 Consensus PT from Analysts

Share on StockTwits

Sangamo Therapeutics Inc (NASDAQ:SGMO) has been given an average rating of “Hold” by the ten brokerages that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $18.80.

SGMO has been the subject of several recent research reports. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 10th. Wedbush set a $11.00 price objective on Sangamo Therapeutics and gave the stock a “hold” rating in a report on Monday, November 19th. JPMorgan Chase & Co. cut Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. Finally, Guggenheim lowered Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 target price for the company. in a research report on Friday, November 9th.

In other news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $12.33, for a total transaction of $61,650.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 25,000 shares of company stock valued at $281,500 over the last 90 days. Corporate insiders own 1.20% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of SGMO. Advisors Asset Management Inc. grew its position in shares of Sangamo Therapeutics by 130.0% in the 2nd quarter. Advisors Asset Management Inc. now owns 12,020 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 6,793 shares during the period. Northern Trust Corp grew its position in shares of Sangamo Therapeutics by 21.0% in the 2nd quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock valued at $18,286,000 after purchasing an additional 223,870 shares during the period. United Services Automobile Association grew its position in shares of Sangamo Therapeutics by 9.2% in the 2nd quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock valued at $818,000 after purchasing an additional 4,860 shares during the period. Peregrine Capital Management LLC grew its position in shares of Sangamo Therapeutics by 0.7% in the 3rd quarter. Peregrine Capital Management LLC now owns 611,493 shares of the biopharmaceutical company’s stock valued at $10,365,000 after purchasing an additional 4,430 shares during the period. Finally, Vanguard Capital Wealth Advisors acquired a new position in shares of Sangamo Therapeutics in the 3rd quarter valued at approximately $322,000. Institutional investors and hedge funds own 62.27% of the company’s stock.

NASDAQ:SGMO traded up $0.49 on Friday, hitting $8.81. 1,099,390 shares of the stock were exchanged, compared to its average volume of 2,471,546. The stock has a market capitalization of $849.41 million, a P/E ratio of -12.59 and a beta of 2.84. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $27.50. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Further Reading: Quiet Period

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Raymond James Financial Services Advisors Inc. Has $821,000 Position in First Republic Bank
Raymond James Financial Services Advisors Inc. Has $821,000 Position in First Republic Bank
John Hancock Multifactor Technology ETF  Position Lowered by Raymond James Financial Services Advisors Inc.
John Hancock Multifactor Technology ETF Position Lowered by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. Decreases Holdings in Oracle Co.
Raymond James Financial Services Advisors Inc. Decreases Holdings in Oracle Co.
Raymond James & Associates Acquires 4,931 Shares of Veeva Systems Inc
Raymond James & Associates Acquires 4,931 Shares of Veeva Systems Inc
Perficient, Inc.  Shares Sold by Globeflex Capital L P
Perficient, Inc. Shares Sold by Globeflex Capital L P
Raymond James  Shares Bought by CSat Investment Advisory L.P.
Raymond James Shares Bought by CSat Investment Advisory L.P.


© 2006-2019 Ticker Report